Inhibition of Bcl-2 protein expression by liposomal...

Details Inhibition of Bcl-2 protein expression by liposomal... Inhibition of Bcl-2 protein expression by liposomal...

2005-12-20

2005-12-20

Guzo, David (Department: 1636)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C435S375000, C435S458000, C424S450000, C536S024500

Reexamination Certificate

active

06977244

ABSTRACT:
The present invention provides novel compositions and methods for use in the treatment of Bcl-2-associated diseases like cancer, specifically, in the treatment of follicular lymphoma (FL). The compositions contain antisense oligonucleotides that hybridize to Bcl-2 nucleic acids, the gene products of which are known to interact with the tumorigenic protein Bcl-2. Used alone, or in conjunction with other antisense oligonucleotides, these compositions inhibit the proliferation of FL cancer cells.

REFERENCES:
patent: 4229360 (1980-10-01), Schneider et al.
patent: 4394448 (1983-07-01), Szoka, Jr. et al.
patent: 4469863 (1984-09-01), Ts'o et al.
patent: 4480041 (1984-10-01), Myles et al.
patent: 4721612 (1988-01-01), Janoff et al.
patent: 4835263 (1989-05-01), Nguyen et al.
patent: 4837028 (1989-06-01), Allen
patent: 4904582 (1990-02-01), Tullis
patent: 4920016 (1990-04-01), Allen et al.
patent: 4924624 (1990-05-01), Suhadolnik et al.
patent: 4950432 (1990-08-01), Mehta et al.
patent: 5015568 (1991-05-01), Tsujimoto et al.
patent: 5030442 (1991-07-01), Uster et al.
patent: 5049388 (1991-09-01), Knight et al.
patent: 5087617 (1992-02-01), Smith
patent: 5094785 (1992-03-01), Law et al.
patent: 5098890 (1992-03-01), Gewirtz et al.
patent: 5100662 (1992-03-01), Bolcsak et al.
patent: 5112962 (1992-05-01), Letsinger et al.
patent: 5135917 (1992-08-01), Burch
patent: 5178875 (1993-01-01), Lenk et al.
patent: 5188897 (1993-02-01), Suhadolnik et al.
patent: 5202429 (1993-04-01), Tsujimoto et al.
patent: 5227170 (1993-07-01), Sullivan
patent: 5248671 (1993-09-01), Smith
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5271941 (1993-12-01), Cho-Chung
patent: 5279833 (1994-01-01), Rose
patent: 5279957 (1994-01-01), Gross
patent: 5320962 (1994-06-01), Stiles et al.
patent: 5324654 (1994-06-01), Bredesen
patent: 5376646 (1994-12-01), Pittrof et al.
patent: 5378825 (1995-01-01), Cook et al.
patent: 5417978 (1995-05-01), Tari et al.
patent: 5459251 (1995-10-01), Tsujimoto et al.
patent: 5527538 (1996-06-01), Baldeschwieler
patent: 5539085 (1996-07-01), Bischoff et al.
patent: 5539094 (1996-07-01), Reed et al.
patent: 5560923 (1996-10-01), Rahman et al.
patent: 5565337 (1996-10-01), Diamond et al.
patent: 5583034 (1996-12-01), Green et al.
patent: 5622852 (1997-04-01), Korsmeyer
patent: 5641662 (1997-06-01), Debs et al.
patent: 5661018 (1997-08-01), Ashley et al.
patent: 5665710 (1997-09-01), Rahman et al.
patent: 5696248 (1997-12-01), Peyman et al.
patent: 5705385 (1998-01-01), Bally et al.
patent: 5734033 (1998-03-01), Reed
patent: 5750669 (1998-05-01), Rosch et al.
patent: 5756122 (1998-05-01), Thierry et al.
patent: 5817811 (1998-10-01), Breipohl et al.
patent: 5831048 (1998-11-01), Schweighoffer et al.
patent: 5831066 (1998-11-01), Reed
patent: 5837838 (1998-11-01), Reed et al.
patent: 5855911 (1999-01-01), Lopez-Berestein et al.
patent: 5874224 (1999-02-01), Bandman et al.
patent: 5874553 (1999-02-01), Peyman et al.
patent: 5891714 (1999-04-01), Ashley et al.
patent: 5908635 (1999-06-01), Thierry
patent: 5976567 (1999-11-01), Wheeler et al.
patent: 5981501 (1999-11-01), Wheeler et al.
patent: 5989912 (1999-11-01), Arrow et al.
patent: 6015886 (2000-01-01), Dale et al.
patent: 6030954 (2000-02-01), Wu et al.
patent: 6034235 (2000-03-01), Sugiyama et al.
patent: 6040181 (2000-03-01), Reed
patent: 6042846 (2000-03-01), Lopez-Berestein et al.
patent: 6096720 (2000-08-01), Love et al.
patent: 6110490 (2000-08-01), Thierry
patent: 6120794 (2000-09-01), Liu et al.
patent: 6120798 (2000-09-01), Allen et al.
patent: 6126965 (2000-10-01), Kasid et al.
patent: 6136965 (2000-10-01), Bruice et al.
patent: 6211162 (2001-04-01), Dale et al.
patent: 6211349 (2001-04-01), Dale et al.
patent: 6277832 (2001-08-01), Sugiyama et al.
patent: 6277981 (2001-08-01), Tu et al.
patent: 6291668 (2001-09-01), Ziegler et al.
patent: 6326487 (2001-12-01), Peyman et al.
patent: 2171589 (1996-03-01), None
patent: WO 88/04924 (1988-07-01), None
patent: WO 89/06977 (1989-08-01), None
patent: WO 90/09180 (1990-08-01), None
patent: WO 90/10488 (1990-09-01), None
patent: WO 91/16901 (1991-11-01), None
patent: WO 92/21330 (1992-12-01), None
patent: WO 93/07883 (1993-04-01), None
patent: WO 93/11245 (1993-06-01), None
patent: WO 93/20200 (1993-10-01), None
patent: WO 93/24653 (1993-12-01), None
patent: WO 94/04545 (1994-03-01), None
patent: WO 94/05259 (1994-03-01), None
patent: WO 95/03788 (1995-02-01), None
patent: WO 95/08350 (1995-03-01), None
patent: WO 95/28497 (1995-10-01), None
patent: WO 96/27663 (1996-09-01), None
patent: WO 96/40062 (1996-12-01), None
patent: WO 97/07784 (1997-03-01), None
patent: WO 98/14172 (1998-04-01), None
patent: WO 98/56905 (1998-12-01), None
patent: WO 00/40595 (2000-07-01), None
patent: WO 02/17852 (2002-03-01), None
Far et al. Concepts to automate the theoretical design of effective antisense oligonucleotides. Bioinformatics. Nov. 2001;17(11):1058-61.
Braasch et al. Novel antisense and peptide nucleic acid strategies for controlling gene expression. Biochemistry. Apr. 9, 2002;41(14):450-10.
Tamm et al. Antisense therapy in oncology: new hope for an old idea? Lancet. Aug. 11, 2001;358(9280):489-97.
Abubakr et al. (1994) Effectiveness of Bcl-2 antisense oliogodeoxynucleotides (AS-ODN) against human follicular small-cleaved cell lymphoma (FSCCL)-SCID mice xenograft model. Blood 84 (10 Suupl 1)374A, Dec. 1994.
Pocock et al. (1993) In vivo suppression of B-cell lymphoma with Bcl-2 antisense oligonucleotides. Blood 82 (10 Suppl 1) 200A, Dec. 1993.
Cotter et al. (1994) Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 9:3049-3055, Oct. 1994.
Ledley (1994) Non-viral gene therapy. Curr. Opin. Biotechnol. 5:626-636.
Rojanasakul (1996) Antisense oligonucleotide therapeutics: drug delivery and targeting. Adv. Drug Delivery Rev. 18:115-131.
Tormo et al. (1996) Antitumor activity of liposomal-bcl-2-antisense oligonucleotides in follicular lymphoma. Proc. Amer. Assoc. Cancer Res. 37:173, Mar. 1996.
Almazan et al. (1996) Methylphosphonate-containing oligonucleotides efficiently and specifically inhibit bcl-2 and erbB-2 expression in vitro. Proc. Amer. Assoc. Cancer Res. 37:353, Mar. 1996.
Agrawal, “Antisense oligonucleotides; towards clinical trials,” TIB Tech, 14(10):376-387, 1996.
Agrawal et al., “Antisense therapeutics: is it as simple as complementary base recognition,” Molecular Medicine Today, 6:72-81, 2000.
Aisenberg, “Coherent view of non-Hodgkin's lymphoma,”J. Clin. Oncol.,13(10):2656-2675, 1995.
Baichwal and Sugden, “Vectors for gene transfer derived from animal DNA viruses: Transient and stable expression of transferred genes,” In: Kucherlapati R, (ed.) Gene transfer. New York: Plenum Press, pp. 117-148, 1986.
Bangham et al., “Diffusion of univalent ions accross the lamellae of swollen phospholipids,”J. Mol. Biol.,13:238-252, 1965.
Benvenisty and Reshif, “Direction introduction of genes into rats and expression of the genes,”Proc. Nat'l Acad. Sci. USA,83:9551-9555, 1986.
Chang et al., “Foreign gene delivery and expression in hepatocytes using a hepatitis B virus vector,” Abstract,Hepatology,14(4):124A, 1991.
Chen and Okayama, “High-efficiency transfection of mammalian cells by plasmid DNA,”Mol. Cell Biol.,7(8):2745-2752, 1987.
Chirila et al., “The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides,”Biomaterials,23:321-342, 2002.
Coffin, “Retroviridae: the viruses and their replication,”In: Virology,Fields et al. (eds.), New York: Raven Press, pp. 1767-1847, 1996.
Cotter et al., “Human Bcl-2 antisense therapy for lymphomas,”Biochimica et Biophysica Acta,1489:97-106, 1999.
Coupar et al., “A general method for the construction of recombinant vaccinia virus expressing multiple foreign genes,”Gene,68:1-10, 1988.
Crooke, “Antisense research and application,” Springer, NY, 1-50, 1998.
Crystal,Science,270:404-410, 1995.
Deamer and Uster, “

Affiliated with

Also associated with

Rating

Inhibition of Bcl-2 protein expression by liposomal... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibition of Bcl-2 protein expression by liposomal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of Bcl-2 protein expression by liposomal... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3515607